Immunogenicity and Safety of MenACWY-TT, a Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine Recently Licensed in the United States for Individuals ≥2 Years of Age

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Aug 10

PMID 35947774

Authors

Gary S Marshall

Stephen I Pelton

Corwin A Robertson

Philipp Oster

Affiliations

Soon will be listed here.

Abstract

Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence. Since some meningococcal vaccines are associated with modest immunogenicity in infants, possible immunological interference upon concomitant administration with some pediatric vaccines, and administration errors resulting from improper reconstitution, opportunities for improvement exist. A quadrivalent conjugate vaccine, MenQuadfi® (Meningococcal [Serogroups A, C, Y, and W] Conjugate Vaccine; Sanofi, Swiftwater, Pennsylvania), was approved in 2020 for the prevention of IMD caused by meningococcal serogroups A, C, W, and Y in individuals ≥2 years of age in the United States. Five pivotal studies and one ancillary study supported approval in the United States; clinical trials in infants are ongoing. Data on the immunogenicity and safety of this vaccine are presented, and its potential value in clinical practice is discussed.

References

Baccarini C, Simon M, Brandon D, Christensen S, Jordanov E, Dhingra M . Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study. Pediatr Infect Dis J. 2020; 39(10):955-960. PMC: 7497415. DOI: 10.1097/INF.0000000000002832. View

Kensinger R, Arunachalam A . Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®. Glycoconj J. 2022; 39(3):381-392. PMC: 9019543. DOI: 10.1007/s10719-022-10050-2. View

Cohn A, MacNeil J, Harrison L, Hatcher C, Theodore J, Schmidt M . Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2009; 50(2):184-91. DOI: 10.1086/649209. View

Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U . Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis. 2015; 38:36-42. DOI: 10.1016/j.ijid.2015.07.003. View

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View

Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein N . Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis. 2012; 54(6):800-4. DOI: 10.1093/cid/cir960. View

Cho B, Clark T, Messonnier N, Ortega-Sanchez I, Weintraub E, Messonnier M . MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach. Vaccine. 2009; 28(3):817-22. DOI: 10.1016/j.vaccine.2009.10.050. View

Stinson C, Burman C, Presa J, Abalos M . Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci. Epidemiol Infect. 2020; 148:e12. PMC: 7019474. DOI: 10.1017/S0950268819002152. View

Guiddir T, Gros M, Hong E, Terrade A, Denizon M, Deghmane A . Unusual Initial Abdominal Presentations of Invasive Meningococcal Disease. Clin Infect Dis. 2018; 67(8):1220-1227. DOI: 10.1093/cid/ciy257. View

10.

Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I . Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J. 2015; 35(1):81-93. DOI: 10.1097/INF.0000000000000930. View

11.

Khatami A, Pollard A . The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010; 9(3):285-98. DOI: 10.1586/erv.10.3. View

12.

De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B . Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015; 33(32):3976-82. DOI: 10.1016/j.vaccine.2015.06.030. View

13.

Pelton S . The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. J Adolesc Health. 2016; 59(2 Suppl):S3-S11. DOI: 10.1016/j.jadohealth.2016.04.012. View

14.

Cohn A, MacNeil J, Harrison L, Lynfield R, Reingold A, Schaffner W . Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. Pediatrics. 2017; 139(2). PMC: 8353579. DOI: 10.1542/peds.2016-2193. View

15.

Lucidarme J, Scott K, Ure R, Smith A, Lindsay D, Stenmark B . An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016; 21(45). PMC: 5144941. DOI: 10.2807/1560-7917.ES.2016.21.45.30395. View

16.

Klein N, Reisinger K, Johnston W, Odrljin T, Gill C, Bedell L . Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2011; 31(1):64-71. DOI: 10.1097/INF.0b013e31823dce5c. View

17.

Powers D, Anderson E, LOTTENBACH K, Mink C . Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis. 1996; 173(4):1014-8. DOI: 10.1093/infdis/173.4.1014. View

18.

Su J, Miller E, Duffy J, Baer B, Cano M . Notes from the Field: Administration Error Involving a Meningococcal Conjugate Vaccine--United States, March 1, 2010-September 22, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(6):161-2. DOI: 10.15585/mmwr.mm6506a4. View

19.

Tseng H, Sy L, Ackerson B, Hechter R, Tartof S, Haag M . Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics. 2016; 139(1). DOI: 10.1542/peds.2016-2084. View

20.

Harcourt B, Anderson R, Wu H, Cohn A, MacNeil J, Taylor T . Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States. Open Forum Infect Dis. 2015; 2(3):ofv117. PMC: 4561371. DOI: 10.1093/ofid/ofv117. View